Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Longer overall survival and similar safety profile were the endpoints in this NEJM piece, comparing those who received osimertinib with those who received a comparator EGFR-TKI.
Internal Medicine March 16th 2020
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH